Sign in
Taking people in United StatesPhase 1/2

Tests virus-fighting T cells for viral infections after transplant or weakened immunity

Tests donor-derived virus-fighting T cells in people with adenovirus, CMV or EBV infection after transplant.

Key facts

Who runs it
Jessie L. Alexander
Where
Palo Alto, United StatesSee the 2 sites
Trial code
Registry title
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Status
Recruiting
Phase
Phase 1/2
People taking part
25 people, planned
Started
30 Apr 2025
Expected to end
1 Jan 2032
Type of study
Interventional
Treatments tested
  • Adenovirus Specific T- Lymphocytes
  • Cytomegalovirus Specific T-Lymphocytes
  • Epstein-Barr Virus Specific T-Lymphocytes
Record updated
14 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for babies, children and adults with a weak immune system. They need an adenovirus, CMV or EBV infection that has not cleared with standard treatment.

Age
1 month to 65 years
Sex
All sexes
Disease stage
Adenovirus, CMV or EBV infection or disease that continues despite standard treatment. Refractory adenovirus or CMV viremia, EBV DNAemia of 1000 IU/mL or more, or EBV lymphoma or lymphoproliferative disease can count.
Earlier treatment
A past allogeneic stem cell transplant, solid organ transplant, primary immunodeficiency, or recent immunosuppressive therapy for cancer or autoimmune disease. The infection must persist despite standard antiviral treatment (at least 14 days for adenovirus and CMV) or rituximab for EBV. People who cannot take these medicines can also join. Steroids must be reduced to less than 1 mg/kg/day prednisone before the infusion.
Biomarker or test result
Adenovirus DNA of 1000 copies/mL or more, CMV DNA of 1,000 IU/mL or more, or EBV DNA of 1000 IU/mL or more in the blood, depending on the infection. EBV in biopsy tissue also counts.

Main reasons for not taking part

  • ATG or Alemtuzumab within 21 days with few T cells (under 10 CD3+ T cells/uL)
  • Active acute GVHD grades II-IV or active severe chronic GVHD
  • Donor lymphocyte infusion within 21 days
  • Active, uncontrolled relapse of cancer (other than EBV lymphoma or lymphoproliferative disorder)
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 38 criteriaShow less

Other criteria

  • Patient Inclusion Criteria
  • Patient, parent, or legal guardian must have given written informed consent, according to FDA guidelines. For patients ≥ 7 years of age who are developmentally able, assent or affirmation will be obtained, if feasible
  • Male or female, 1 month through 65 years old, inclusive, at the time of informed consent
  • Prior allogeneic hematopoietic stem cell transplant, AND/OR prior solid organ transplant (liver, kidney, lung and/or heart, intestinal, pancreatic, and/or multivisceral), AND/OR diagnosis of primary immunodeficiency AND/OR current/recent administration of immunosuppressive therapy for cancer or autoimmune disease
  • If receiving steroids, must be able to taper dose to less than 1 mg/kg/day prednisone (or equivalent) prior to cellular infusion
  • Negative pregnancy test for females ≥10 years old or who have reached menarche, unless surgically sterilized or post-menopausal
  • Diagnosis of Adenovirus, CMV, or EBV infection, persistent despite standard therapy
  • Adenovirus Infection or Disease (at minimum, one of the below sub-criteria must be met):
  • Active adenovirus infection: (i.e. gastroenteritis, pneumonia, hemorrhagic cystitis, hepatitis, pancreatitis, meningitis) defined as the demonstration of adenovirus by biopsy specimen from affected site(s) (by culture or histology), or the detection of adenovirus by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents)
  • Refractory adenoviremia: defined as DNAemia ≥1000 copies/mL or <1 log decrease after at least 2 weeks of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents)
  • Intolerance of or contraindication to antiviral medications
  • CMV Infection or Disease (at minimum, one of the below sub-criteria must be met):
  • Active CMV infection: (i.e. pneumonia, meningitis, retinitis, hepatitis, hemorrhagic cystitis, and/or gastroenteritis) defined as the demonstration of CMV by biopsy specimen from affected site(s) (by culture or histology) or the detection of CMV by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents)
  • Refractory CMV viremia: defined as the continued presence of DNAemia, with ≥1,000 IU/mL or <1 log decrease after at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents)
  • Intolerance of or contraindication to antiviral medications
  • EBV Infection or Disease (at minimum, one of the below sub-criteria must be met):
  • EBV DNAemia ≥1000 IU/mL, persistent despite 2 doses of rituximab,
  • Biopsy proven lymphoma or lymphoproliferative disease with EBV genomes detected in tumor cells by immunocytochemistry (i.e. EBER positive) or in situ PCR,
  • Clinical or imaging findings consistent with EBV lymphoma or lymphoproliferation with current or recent elevated EBV viral load in peripheral blood in a patient where biopsy is deemed too high risk,
  • Failure of antiviral therapy, as determined by one of the two bullets below after two weeks of anti-CD20 targeted therapy such as rituximab, i. There was an increase or less than 50% response at sites of lymphoma disease or lymphoproliferation; There was a rise or a fall of less than 50% in EBV viral load in peripheral blood
  • Intolerance or contraindication to rituximab; Patient Exclusion Criteria:
  • Received ATG or Alemtuzumab within 21 days of viral-specific T cell infusion and a lack of evidence of T cell survival, defined by <10 CD3+ T cells/uL (in unique situations, plasmapheresis may be considered)
  • Active acute GVHD grades II-IV
  • Active severe chronic GVHD
  • Received donor lymphocyte infusion, with the exception of a fraction of an umbilical cord blood, within 21 days of planned viral-specific T cell infusion. Subjects receiving a fraction of an umbilical cord blood within 21 days of the viral-specific T cell infusion will not be excluded
  • Active and uncontrolled relapse of malignancy (other than EBV+ post-transplant lymphoproliferative disorder or lymphoma)
  • Anticipated initiation of new lymphotoxic therapy within 4 weeks of viral-specific T cell infusion
  • Patients who are pregnant or lactating
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, or concomitant medications, which, in the opinion of the investigator, may pose additional risks to participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study; Donor Inclusion Criteria
  • Age ≥ 12*
  • Able to understand and sign the consent/assent to the procedure
  • Partial (2/6 or more) HLA match to the recipient
  • A pediatric donor could be selected as a donor only if a suitable adult donor is not available (as attested by the research team) or is ineligible according to FACT requirements. For pediatric donors:; Related to the recipient; Apheresis does not need a blood prime before the procedure; Adequate peripheral venous access; Explicit evaluation of the donors' willingness to donate cells, as attested by the research team; Must have understanding that they are helping their ill relative, as attested by the research team; Will gain emotional/psychological benefit from their ability to help and want to donate for a relative, as attested by the research team; Inclusion of minor donors that are not relatives of the recipient will need to be evaluated on a case-by-case basis for the IRB to evaluate the potential benefit to these participants (whether they will receive an emotional and psychological boost from helping the recipient) *If the only suitable donor is less than 12 years old, a single patient exception to this inclusion criteria will be submitted and approved by the IRB before obtaining the donor's assent and their LAR consent; Donor Exclusion Criteria
  • Donor is pregnant
  • Donor is HIV positive
  • Donor is positive for hepatitis B and/or hepatitis C
  • Deemed to be a high-risk donor based on responses to donor risk questionnaire
  • Deemed high risk due to preexisting medical condition or abnormal lab results

Where in United States

  • Lucile Packard Children's HospitalPalo Alto, United StatesContact: Jessie L Alexander, MDTaking people
  • Jessie AlexanderPalo Alto, United StatesNo longer taking part

About the trial

What the trial wants to find out

The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of allogeneic HCT or solid organ transplant (SOT), or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to prepare patient-specific products, and cost associated with products that may not be used limits their value. In this trial, we will evaluate viral specific T cells generated by gamma capture technology. Eligible patients will include HCT and/or SOT recipients, and/or patients with compromised immunity who have adenovirus, CMV, or EBV infection or refractory viremia that is persistent despite standard therapy. Infusion of the cellular product will be assessed for safety and efficacy.

The group in the trial

  • Viral Specific T-LymphocytesTreatment being tested

    Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.

    Treatment: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, and Epstein-Barr Virus Specific T-Lymphocytes

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Viral Specific T-Lymphocytes by Cytokine Capture System (CCS) to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus After Hematopoietic Cell Transplantation or Solid Organ Transplantation and in Patients With Compromised Immunity
Plain-language title
Tests virus-fighting T cells for viral infections after transplant or weakened immunityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 August 2025